The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine’s subjective effects
Francisco González-espejito, Laura Esteban Rodríguez, Eduardo J. Pedrero Pérez, Jonathan Dickinson, Maja Kohek, Rafael G. Dos Santos, Jaime E. C. Hallak, Miguel Ángel Alcázar‐córcoles, Brianna Morgan, José Carlos Bouso
PLoS ONE October 13, 2025 DOI: 10.1371/journal.pone.0333296 via OpenAlex
Summary
AI-generated from the abstractIbogaine, a compound from the iboga plant used in traditional Bwiti rituals, shows promise for treating opioid dependence and neurological conditions, but existing tools fail to capture its dream-like subjective effects. A new 70-item Ibogaine Experience Scale (IES) was developed from a prior qualitative study and tested with 499 participants in neuropsychiatric and substance use treatment settings. The final scale has seven factors—including narrative visions, visual changes, discomfort, cosmic visions, introspection, somatosensory sensitivity, and dissociation—explaining 53.9% of variance, with excellent statistical fit and high internal consistency. The IES offers a reliable way to measure ibogaine's multidimensional effects for research and clinical use.
Study at a glance
| Characteristics | Scale development and validation study Qualitative Peer reviewed |
|---|---|
| Sample size | 499 |
| Population | Participants across two clinical settings: cohort neuropsychiatric treatments (n = 381) and substance use disorder treatments (n = 118) |
| Intervention | Ibogaine |
| Keywords | Psychometrics Exploratory factor analysis Scale ratio Internal consistency Item response theory |
| Key finding | The 70-item Ibogaine Experience Scale (IES) has a seven-factor structure with excellent fit and high internal consistency, providing a reliable instrument for quantifying ibogaine's distinctive subjective effects. |
Abstract
Ibogaine, an indole alkaloid derived from the root bark of Tabernanthe iboga, has long been used in traditional Bwiti healing rituals and shows promise for treating opioid dependence and neurological conditions, but existing psychometric tools fail to capture its distinctive subjective/oneiric (dream-like) effects. To address this gap, we developed the 70-item Ibogaine Experience Scale (IES) through an iterative process informed by a prior qualitative study (n = 20) that identified eight experiential domains. A preliminary 144-item version was completed on site with a mobile device within 48 hours of treatment by 499 participants across two clinical settings-cohort neuropsychiatric treatments (n = 381) and substance use disorder treatments (n = 118). We employed exploratory graph analysis, parallel analysis on polychoric correlations, and iterative item-reduction (Gulliksen's Pool, MIREAL, MSA) to refine the scale. Semi-confirmatory factor analysis used Robust Unweighted Least Squares (RULS) with LOSEFER correction, oblimin rotation, and multiple fit indices (CFI, NNFI, GFI, AGFI, RMSR, WRMR). Cronbach's α, McDonald's ω, H indices, EAP reliability, FDI, ORION, SR, and EPTD assessed internal consistency and factorial quality. The final structure comprises seven factors-Narrative and symbolic visions; Visual changes; Discomfort and challenge; Cosmic/Archetypal Visions; Introspection and personal transformation; Somatosensory hypersensitivity and physiological activation; Dissociation-explaining 53.9% of variance, with excellent fit (CFI = .991; GFI = .983; RMSR = .041; WRMR = .038) and high internal consistency (α = .948; ω = .946; subscale ω = .65-.91). Two subscales exhibited small gender effects. The IES provides a reliable, phenomenologically rich instrument for quantifying ibogaine's distinctive subjective effects. It supports research and clinical assessment by capturing the multidimensional, oneiric/dream-like nature of the ibogaine experience. Future work should confirm this structure in independent, culturally diverse cohorts and explore predictive links between IES domains and therapeutic outcomes.